Have an account? Log in.
I don't have an account.
Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $18 to $24.
William Blair analyst Matt Larew upgrades 10x Genomics (NASDAQ:TXG) from Market Perform to Outperform.
William Blair upgrades 10x Genomics, citing AI-driven data demand, improving execution and Xenium validation as key growth drivers.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.